Surmodics (Nasdaq:SRDX) today announced the successful early clinical use of its Pounce LP thrombectomy system.
Eden Prairie, Minnesota-based Surmodics designed the LP (low-profile) thrombectomy system for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature. It performs this removal in vessels between 3.5 mm and 6 mm in diameter.
It introduced the original Pounce system in 2021, with the LP version receiving FDA clearance in June 2023. Pounce LP remains in a limited market evaluation and Surmodics expects a full commercial launch once it completes the evaluation.
Dr. Lucas Ferrer Cardona was the first physician to use Pounce LP. Cardona serves as a vascular surgeon at the Dell Seton Medical Center at the University of Texas Hospital. He said Pounce LP helped restore blood flow to the foot for a limb-threatened patient.
“I believe this device holds great promise in filling a major gap in our treatment algorithm,” Cardona said.
Dr. Elizabeth Genovese, a vascular surgeon at the Hospital of the University of Pennsylvania also got an early look at Pounce LP. A user of the original Pounce, Genovese used the LP version to revascularize a patient with arterial occlusions in both the anterior tibial and peroneal arteries. She reported an optical outcome that she deemed impossible without the device.
Surmodics President and CEO Gary Maharaj said the system can extend the range of treatment for the company’s Pounce platform to include the removal of organized thrombotic or embolic clots from the iliac arteries in the pelvis down to tibial vessels below the knee.
“We’re very pleased with the successful early clinical use of the Pounce LP thrombectomy system,” Maharaj said. “The Pounce LP system’s ability to capture and remove these unexpected emboli adds yet more value to this device for BTK revascularization.”
